These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 24085340)

  • 1. Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis.
    Ratzer R; Søndergaard HB; Christensen JR; Börnsen L; Borup R; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Dec; 19(14):1841-8. PubMed ID: 24085340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
    Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
    Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global transcriptome profiling of mild relapsing-remitting versus primary progressive multiple sclerosis.
    Koch MW; Ilnytskyy Y; Golubov A; Metz LM; Yong VW; Kovalchuk O
    Eur J Neurol; 2018 Apr; 25(4):651-658. PubMed ID: 29316044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study.
    Knapp R; Hardtstock F; Krieger J; Wilke T; Maywald U; Chognot C; Muros-Le Rouzic E; Craveiro L
    Mult Scler Relat Disord; 2022 Dec; 68():104245. PubMed ID: 36306609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis by phenotype in Germany.
    Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
    Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole transcriptome analysis of multiple Sclerosis patients reveals active inflammatory profile in relapsing patients and downregulation of neurological repair pathways in secondary progressive cases.
    Nali LH; Olival GS; Sousa FTG; de Oliveira ACS; Montenegro H; da Silva IT; Dias-Neto E; Naya H; Spangenberg L; Penalva-de-Oliveira AC; Romano CM
    Mult Scler Relat Disord; 2020 Sep; 44():102243. PubMed ID: 32559700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific alterations in NKG2D
    Carmena Moratalla A; Carpentier Solorio Y; Lemaître F; Farzam-Kia N; Da Cal S; Guimond JV; Haddad E; Duquette P; Girard JM; Prat A; Larochelle C; Arbour N
    Mult Scler Relat Disord; 2023 Mar; 71():104542. PubMed ID: 36716577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: A Danish nationwide population-based study.
    Blinkenberg M; Kjellberg J; Ibsen R; Magyari M
    Mult Scler Relat Disord; 2020 Nov; 46():102567. PubMed ID: 33296969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of Polish patients with primary progressive multiple sclerosis.
    Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
    Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis.
    Booth DR; Arthur AT; Teutsch SM; Bye C; Rubio J; Armati PJ; Pollard JD; Heard RN; Stewart GJ;
    J Mol Med (Berl); 2005 Oct; 83(10):822-30. PubMed ID: 16075257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis.
    Boppana S; Mindur JE; Balashov KE; Dhib-Jalbut S; Ito K
    J Neuroimmunol; 2013 Dec; 265(1-2):68-74. PubMed ID: 24200257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.
    Romme Christensen J; Börnsen L; Ratzer R; Piehl F; Khademi M; Olsson T; Sørensen PS; Sellebjerg F
    PLoS One; 2013; 8(3):e57820. PubMed ID: 23469245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis.
    Filion LG; Matusevicius D; Graziani-Bowering GM; Kumar A; Freedman MS
    Clin Immunol; 2003 Feb; 106(2):127-38. PubMed ID: 12672403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Suitable Reference Genes for Peripheral Blood Mononuclear Cell Subset Studies in Multiple Sclerosis.
    Oturai DB; Søndergaard HB; Börnsen L; Sellebjerg F; Christensen JR
    Scand J Immunol; 2016 Jan; 83(1):72-80. PubMed ID: 26395032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
    J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Choi IY; Lee P; Adany P; Hughes AJ; Belliston S; Denney DR; Lynch SG
    Mult Scler; 2018 Jul; 24(8):1029-1038. PubMed ID: 28569645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression.
    Mancuso R; Hernis A; Agostini S; Rovaris M; Caputo D; Clerici M
    J Transl Med; 2015 May; 13():148. PubMed ID: 25947625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS.
    Huijbregts SC; Kalkers NF; de Sonneville LM; de Groot V; Reuling IE; Polman CH
    Neurology; 2004 Jul; 63(2):335-9. PubMed ID: 15277630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis.
    Planche V; Gibelin M; Cregut D; Pereira B; Clavelou P
    Eur J Neurol; 2016 Feb; 23(2):282-9. PubMed ID: 25903918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining evidence from four immune cell types identifies DNA methylation patterns that implicate functionally distinct pathways during Multiple Sclerosis progression.
    Ewing E; Kular L; Fernandes SJ; Karathanasis N; Lagani V; Ruhrmann S; Tsamardinos I; Tegner J; Piehl F; Gomez-Cabrero D; Jagodic M
    EBioMedicine; 2019 May; 43():411-423. PubMed ID: 31053557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.